Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Spiera

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Rheumatology (Oxford, England)|March 15, 2025
Belumosudil in diffuse cutaneous systemic sclerosis: a randomised, double-blind, open-label extension, placebo-controlled, Phase 2 studyLorinda Chung, Richard M Silver, Virginia Steen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 5, 2019
Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated VasculitisZachary S Wallace, Xiaoqing Fu, Katherine Liao, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of TocilizumabJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Annals of the Rheumatic Diseases|October 8, 2020
Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvementKimberly Showalter, Robert Spiera, Cynthia Magro, et al.
Annals of Internal Medicine|April 20, 2005
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) StudyPeter A Merkel, Grace H Lo, Janet T Holbrook, et al.
The Journal of Rheumatology|April 21, 2007
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestationsJodi K Sebastian, Alfred D Mahr, Sohail S Ahmed, et al.
Arthritis and Rheumatism|December 16, 2003
Domains of health-related quality of life important to patients with giant cell arteritisDavid B Hellmann, Misty L Uhlfelder, John H Stone, et al.
Rheumatology (Oxford, England)|June 25, 2022
A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosisJennifer M Franks, Diana M Toledo, Viktor Martyanov, et al.
Arthritis Research & Therapy|October 15, 2023
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritisWolfgang A Schmidt, Bhaskar Dasgupta, Jennifer Sloane, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 27, 2020
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic SclerosisRobert Spiera, Laura Hummers, Lorinda Chung, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Rheumatology (Oxford, England)|March 15, 2025
Belumosudil in diffuse cutaneous systemic sclerosis: a randomised, double-blind, open-label extension, placebo-controlled, Phase 2 studyLorinda Chung, Richard M Silver, Virginia Steen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 5, 2019
Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated VasculitisZachary S Wallace, Xiaoqing Fu, Katherine Liao, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of TocilizumabJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Annals of the Rheumatic Diseases|October 8, 2020
Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvementKimberly Showalter, Robert Spiera, Cynthia Magro, et al.
Annals of Internal Medicine|April 20, 2005
Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) StudyPeter A Merkel, Grace H Lo, Janet T Holbrook, et al.
The Journal of Rheumatology|April 21, 2007
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestationsJodi K Sebastian, Alfred D Mahr, Sohail S Ahmed, et al.
Arthritis and Rheumatism|December 16, 2003
Domains of health-related quality of life important to patients with giant cell arteritisDavid B Hellmann, Misty L Uhlfelder, John H Stone, et al.
Rheumatology (Oxford, England)|June 25, 2022
A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosisJennifer M Franks, Diana M Toledo, Viktor Martyanov, et al.
Arthritis Research & Therapy|October 15, 2023
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritisWolfgang A Schmidt, Bhaskar Dasgupta, Jennifer Sloane, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 27, 2020
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic SclerosisRobert Spiera, Laura Hummers, Lorinda Chung, et al.
Pageof 10